2Arem R, Padayatti S, Saliby AH, et al. Thyroid mierocarcinoma: prevalence, prognosis, and management[ J]. Endocrine Practise, 1999,5:148-156.
3Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002[J]. JAMA,2006,295(18) :2164-2167.
4Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Management Guidelines for patients with thy- roid nodulesand differentiated thyroid cancer[J]. Thyroid,2009, 19(11) :1167-1214.
5Ito Y, Miyauchi A, Inoue H, et al. An observational trim ibr pa- pillary thyroid microcarcinoma in Japanese patients [ J ]. World J Surg,2010 ,34 :28-35.
6Mehanna H, A1-Maqbili T, Carter B, et al. Differences in the re- currence and mortality outcomes rates of incidental and noninci- dental papillary thyroid mic A systematic review and meta-analysis of 21 329 person-years of follow-up [J]. J Clin Endocrinol Metab, 2014,99 (8) : 2834-2843.
7McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer[J]. Proc Natl Acad Sci USA,2014,111(16) :E1600- E1609.
8Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary car- cinomas due to BRAF and p53 mutations [J]. Cancer, 2005, 103 ( 11 ) :2261-2268.
9Chiacchio S, Lorenzoni A, Boni G, et al. Anaplastic thyroid can- cer: prevalence, diagnosis and treatment [J]. Minerva Endocri- nol, 2008,33 (4) : 341-357.
10Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence [J]. J Clin Oncol, 2014, 32(25): 2718-2726.
